NCT07158853 Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
| NCT ID | NCT07158853 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Minnesota |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-04 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2026-02-04 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of this study is to investigate the added benefit of a neuromodulation intervention in individuals taking medication for treatment for Opioid Use Disorder(OUD).
Eligibility Criteria
Inclusion Criteria: * Ability to provide consent and comply with study procedures * Diagnostic and Statistical Manual of Mental Disorders criteria for OUD * Undergoing medication treatment for OUD. Participants may have current comorbid drug use, but primary diagnosis must be OUD * Intention to remain in the study until intervention completion. Exclusion Criteria: * Any medical condition with neurological sequelae * Head injury resulting in skull fracture or loss of consciousness of \>30 minutes * Any tDCS or MRI contraindication (tDCS: history of seizures, metallic cranial plates/screws or implanted device, history of eczema on scalp. MRI: unapproved metallic implants, pacemakers or any other implanted electrical device, shrapnel, metallic braces, non-removable body piercings, pregnancy, breathing or movement disorder, or claustrophobia) * Any psychotic disorder (participants with other treated and stable psychiatric disorders will be included) * Presence of a condition that would render study measures impossible to administer or interpret * Age younger than 18 * Primary current substance use disorder on a substance other than opioids except for caffeine or nicotine * In treatment instead of jail * Pregnancy * Disrespectful behavior towards the investigators and staff.
Contact & Investigator
Jazmin Camchong, PhD
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07158853 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07158853 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07158853 currently recruiting?
Yes, NCT07158853 is actively recruiting participants. Contact the research team at cahil138@umn.edu for enrollment information.
Where is the NCT07158853 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07158853 clinical trial?
NCT07158853 is sponsored by University of Minnesota. The principal investigator is Jazmin Camchong, PhD at University of Minnesota. The trial plans to enroll 40 participants.